The rapid global development of cell-free exosome therapy is generating interest among Taiwanese patients who are informed about the latest regenerative science. However, domestic access to exosome treatment remains limited under TFDA regulations. Our clinic in Chiang Mai, approximately four hours from Taipei Taoyuan Airport, offers exosome therapy with Mandarin-speaking clinical staff and coordinated follow-up with your Taiwanese physician.
Exosome therapy uses cell-free extracellular vesicles to deliver regenerative signalling molecules directly to damaged tissue. As a cell-free biological, exosomes carry growth factors, RNA, and proteins that promote tissue repair without the complexity of live cell transplantation. Treatment involves targeted delivery of purified exosomes to affected areas, often combined with other regenerative modalities for enhanced outcomes. For a comprehensive understanding of the science, evidence, and treatment process, visit our full Exosome Therapy page.
The cell-free nature of exosome therapy appeals to Taiwanese patients who want regenerative benefits with minimal downtime and lower immunological risk compared to cell-based treatments. Treatment programmes are shorter than stem cell protocols, typically three to five days, making it practical for patients travelling from overseas. Mandarin-speaking coordination, significant cost savings compared to any limited domestic options, and structured physician follow-up make the process straightforward.
Exosomes are nanoscale vesicles that carry biological signals between cells, promoting tissue repair and modulating inflammation.
Exosome therapy is cell-free, delivering only the signalling molecules rather than whole cells.
Typically three to five days in Chiang Mai.
Yes. It is frequently combined with stem cell and anti-ageing protocols.
Minimal to none. Most patients resume activities immediately.
Exosome therapy is not widely available in Taiwan due to regulatory restrictions. Thailand offers regulated access under medical supervision.
The TFDA has not established a regulatory pathway for exosome therapy, classifying it as investigational. There is currently no commercial clinical access in Taiwan outside of limited research settings.
No. The 特管辦法 (Regenerative Medicine Act) does not currently include exosome therapy within its defined categories of approved regenerative treatments, leaving Taiwanese patients without a domestic clinical pathway.
Yes. The approximately 4-hour direct flight from Taipei Taoyuan to Chiang Mai makes it very practical. Our Mandarin-speaking coordinator arranges airport transfers and accommodation.